Abstract
Tissue hypoxia may occur in many diseases, specifically during the occurrence and growth of malignant solid-tumors. Targeting hypoxia is one of the most significant characteristics of tumors in diagnosis, monitoring, and treatment. This review summarizes the current oxygen-sensitive imaging agents used to target tumor hypoxia, including positron-emission computed tomography/single photon-emission computed tomography radionuclide labeled tracers, magnetic resonance imaging contrast agents for hypoxia detection, and hypoxia-sensitive optical imaging probes. Researchers have utilized nanotechnology as a useful toolkit to improve the effects of oxygen-sensitive imaging agents. We emphasize the progress and influence of nanotechnology in these materials and technologies. This review demonstrates that hypoxia imaging agents have promising prospects, and may provide helpful information for tumor diagnosis and prognosis.
Keywords: Imaging agents, magnetic resonance, optical imaging, oxygen sensing, radiology, tumor hypoxia.
Current Medicinal Chemistry
Title:Imaging Agents in Targeting Tumor Hypoxia
Volume: 23 Issue: 17
Author(s): Yun Zeng, Jingwen Ma, Shaojuan Zhang and Daocheng Wu
Affiliation:
Keywords: Imaging agents, magnetic resonance, optical imaging, oxygen sensing, radiology, tumor hypoxia.
Abstract: Tissue hypoxia may occur in many diseases, specifically during the occurrence and growth of malignant solid-tumors. Targeting hypoxia is one of the most significant characteristics of tumors in diagnosis, monitoring, and treatment. This review summarizes the current oxygen-sensitive imaging agents used to target tumor hypoxia, including positron-emission computed tomography/single photon-emission computed tomography radionuclide labeled tracers, magnetic resonance imaging contrast agents for hypoxia detection, and hypoxia-sensitive optical imaging probes. Researchers have utilized nanotechnology as a useful toolkit to improve the effects of oxygen-sensitive imaging agents. We emphasize the progress and influence of nanotechnology in these materials and technologies. This review demonstrates that hypoxia imaging agents have promising prospects, and may provide helpful information for tumor diagnosis and prognosis.
Export Options
About this article
Cite this article as:
Zeng Yun, Ma Jingwen, Zhang Shaojuan and Wu Daocheng, Imaging Agents in Targeting Tumor Hypoxia, Current Medicinal Chemistry 2016; 23 (17) . https://dx.doi.org/10.2174/0929867323666160321122023
DOI https://dx.doi.org/10.2174/0929867323666160321122023 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Insect Larvae: A New Platform to Produce Commercial Recombinant Proteins
Current Pharmaceutical Biotechnology Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Mini-Reviews in Medicinal Chemistry Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Intramolecular Cyclisation of β-Aryl-β-Amino Acids in the Design of Novel Heterocyclic Systems with Therapeutic Interest: An Unfailing Source of Diversity
Current Medicinal Chemistry The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets HIV Infection Induces Morphometrical Changes on the Oral (Buccal Mucosa and Tongue) Epithelial Cells
Current HIV Research The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals
Current Medicinal Chemistry Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets